```html

Graft Rejection

What is Graft Rejection?

Graft rejection is the immune system’s response against transplanted tissue or an organ (the “graft”). After a transplant, the body may recognize the donor tissue as foreign and activate immune cells that attack and damage the graft, potentially leading to loss of function. Rejection can be hyperacute, acute, or chronic, each with different timing and mechanisms. Understanding why rejection occurs and how to detect it early is essential for improving transplant survival and patient outcomes.<sup>[1][2]</sup>

Common Causes

The trigger for graft rejection is typically an immune mismatch, but several conditions and factors increase the risk:

• HLA mismatch: Differences in human leukocyte antigen (HLA) proteins between donor and recipient.
• Pre‑existing sensitization: Prior transfusions, pregnancies, or previous transplants create antibodies that can attack a new graft.
• Non‑adherence to immunosuppressive medication: Missing doses allows immune cells to activate.
• Infections: Viral (e.g., CMV, EBV) or bacterial infections can stimulate the immune system and precipitate rejection.
• Ischemia‑reperfusion injury: Damage that occurs when blood flow returns to the organ after transplantation.
• Drug interactions: Certain antibiotics, antifungals, or seizure meds can lower blood levels of immunosuppressants.
• Donor‑derived immune cells (passenger leukocytes): These cells can provoke a response in the recipient.
• Autoimmune disease in the recipient: Conditions such as lupus increase immune reactivity.
• Risky lifestyle factors: Smoking, excessive alcohol, and uncontrolled hypertension can impair graft tolerance.
• Genetic polymorphisms: Variations in cytokine genes (e.g., IL‑10, TNF‑α) influence rejection susceptibility.

Associated Symptoms

The clinical picture varies with the type of organ transplanted and the form of rejection, but common warning signs include:

• Fever or chills – especially in acute cellular rejection.
• Pain or tenderness over the transplanted organ (e.g., abdominal pain after liver transplant).
• Decreased organ function:
  • Kidney: reduced urine output, swelling, rising creatinine.
  • Liver: jaundice, dark urine, pale stools.
  • Heart: shortness of breath, palpitations, low cardiac output.
  • Lung: cough, wheezing, falling oxygen saturation.
• Skin changes: rash or erythema over the graft site (common in skin or face transplants).
• Bleeding or bruising at the surgical site, suggesting inflammation.
• General malaise, fatigue, and weight loss due to chronic rejection.

When to See a Doctor

Prompt medical attention can save a graft. Seek care immediately if you experience any of the following:

• Fever > 38°C (100.4°F) that does not resolve with antipyretics.
• Sudden decrease in urine output (kidney) or a sharp rise in blood‑creatinine levels.
• New or worsening shortness of breath, chest pain, or palpitations (heart/lung graft).
• Severe abdominal pain, nausea, or vomiting after abdominal organ transplant.
• Unexplained swelling, yellowing of the skin or eyes, or persistent dark urine.
• Any signs of infection (e.g., wound drainage, redness, warmth) that could trigger rejection.
• Missed or inconsistent doses of immunosuppressive medication.

Diagnosis

Diagnosing graft rejection involves a combination of laboratory tests, imaging, and sometimes tissue sampling:

1. Laboratory Monitoring

• Blood chemistry: Rising creatinine (kidney), liver enzymes (AST/ALT), or cardiac enzymes (troponin).
• Complete blood count (CBC): Elevated white blood cells may indicate inflammation.
• Immunosuppressant drug levels: Sub‑therapeutic levels often precede rejection.
• Donor‑specific antibody (DSA) testing: Detects circulating antibodies against donor HLA.

2. Imaging Studies

• Ultrasound (with Doppler) for kidney and liver graft perfusion.
• Chest X‑ray or CT scan for lung and heart transplants.
• Echocardiography for cardiac function.

3. Tissue Biopsy

The gold standard, especially for acute cellular rejection, is a core needle or surgical biopsy of the graft. Pathologists look for lymphocytic infiltrates, endothelial damage, or fibrosis (chronic rejection). <sup>[3]</sup>

4. Molecular & Genomic Tools

Emerging assays such as gene expression profiling (e.g., AlloMap for heart transplants) can detect early immune activation before clinical signs appear. <sup>[4]</sup>

Treatment Options

Therapy is tailored to the type and severity of rejection, the transplanted organ, and the patient’s overall health.

1. Pharmacologic Therapy

• Corticosteroids: High‑dose IV methylprednisolone is first‑line for acute cellular rejection.
• Antithymocyte globulin (ATG) or alemtuzumab: Depletes T‑cells; used for steroid‑resistant or severe rejection.
• Mycophenolate mofetil or mycophenolic acid: Inhibits lymphocyte proliferation; often added or increased.
• Calcineurin inhibitors (tacrolimus, cyclosporine): Adjusted to maintain therapeutic trough levels.
• mTOR inhibitors (sirolimus, everolimus): Helpful in chronic rejection or when calcineurin toxicity occurs.
• Plasmapheresis + IVIG: Used for antibody‑mediated rejection (AMR) to remove circulating donor‑specific antibodies.

2. Supportive & Home‑Based Measures

• Strict adherence to the prescribed immunosuppressive regimen – use pill organizers or smartphone reminders.
• Maintain a balanced diet low in sodium and saturated fat to protect kidney and heart grafts.
• Stay hydrated (unless fluid restriction is ordered) to help kidney perfusion.
• Regular physical activity appropriate for your transplant type (e.g., walking, light resistance training).
• Avoid tobacco, limit alcohol, and manage stress – all reduce immune activation.

3. Management of Underlying Triggers

• Prompt treatment of infections (antivirals for CMV, antibiotics for bacterial infections).
• Adjust concomitant medications that interfere with immunosuppressant metabolism.
• Control comorbidities such as hypertension, diabetes, and hyperlipidemia.

Prevention Tips

While rejection can never be completely eliminated, the following strategies dramatically lower risk:

• Pre‑transplant evaluation: Comprehensive HLA matching and antibody screening.
• Education on medication adherence: Review dosing schedules at every clinic visit.
• Therapeutic drug monitoring: Regular blood draws to keep immunosuppressant levels in target ranges.
• Vaccinations: Up‑to‑date flu, pneumococcal, and COVID‑19 vaccines reduce infection‑driven rejection.
• Infection prophylaxis: Trimethoprim‑sulfamethoxazole for Pneumocystis jirovecii, antiviral prophylaxis for CMV as indicated.
• Lifestyle modifications: Stop smoking, limit alcohol, maintain a healthy weight, and follow a low‑salt diet.
• Regular follow‑up: Keep all post‑transplant appointments for labs, imaging, and biopsies when recommended.
• Stress reduction techniques: Mindfulness, yoga, or counseling can modulate immune stress responses.

Emergency Warning Signs

References

1. Mayo Clinic. Organ transplant rejection. Updated 2023. https://www.mayoclinic.org
2. National Institutes of Health. Transplantation: The Immune Response. 2022. NIH Bookshelf
3. Cleveland Clinic. Biopsy interpretation in solid‑organ transplantation. 2021.
4. U.S. Food and Drug Administration. AlloMap® Heart Transplant Surveillance Test. 2020.
5. World Health Organization. Guidelines on the Care of the Transplant Recipient. 2022.
6. Centers for Disease Control and Prevention. Vaccines for Transplant Recipients. 2023.

```